1. Convert an immediate-release tacrolimus regimen to extended-release tacrolimus on the basis of patient-specific factors.

2. Assess the risk-benefit of calcineurin inhibitor (CNI) minimization strategies in solid organ transplant recipients.

3. Develop a patient care plan for transition to an alternative immunosuppression regimen that minimizes CNI exposure.

4. Evaluate CYP3A5 genotype data to predict the tacrolimus metabolism phenotype.

5. Apply patient-specific pharmacogenetics to selecting a posttransplant tacrolimus regimen.

1. Design a maintenance plan for immunosuppression for an intestinal transplant (ITx) recipient.

2. Distinguish patient scenarios that may warrant the use of adjunctive or alternative maintenance agents in an ITx recipient.

3. Apply evidence of allogenic islet cell maintenance immunosuppressive outcomes to patient scenarios.

4. Analyze maintenance immunosuppressive regimens for face, limb, and uterus transplant (UTx) recipients.

5. Convert maintenance immunosuppressive medications for face, limb, and UTx recipients to alternative or adjunctive agents on the basis of patient-specific factors.

1. Assess risk factors for developing posttransplant diabetes (PTD) in solid organ transplant (SOT) recipients.

2. Develop a patient care plan for managing PTD in SOT recipients.

3. Analyze the role of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) or sodium-glucose cotransporter-2 (SGLT2) inhibitors for managing PTD according to available evidence for their use in SOT recipients.

4. Assess risk factors for developing osteoporosis in SOT recipients.

5. Develop a patient care plan for managing osteoporosis after transplantation in SOT recipients.

6. Analyze the risk-benefit of modifying immunosuppressive regimens after transplantation to alleviate the risk of developing PTD and/or osteoporosis.

1. Evaluate risk factors for developing malignancy after transplantation.

2. Develop a patient care plan for managing posttransplant lymphoproliferative disorders (PTLDs) in solid organ transplant recipients (SOTRs).

3. Evaluate the evidence for modifications to maintenance immunosuppressive regimens in SOTRs with Kaposi sarcoma.

4. Design a monitoring plan to evaluate the response to the therapeutic options used to treat skin cancer in SOTRs.

5. Assess current data on the use of immune checkpoint inhibitors (ICIs) in SOTRs.

1. Assess the epidemiology and risk factors for the common fungal infections encountered in solid organ transplant recipients.

2. Distinguish the spectrum of activity and pharmacologic properties of common antifungals.

3. Justify appropriate posttransplant antifungal prophylaxis according to organ type and other patient-specific considerations.

4. Design an optimal antifungal treatment regimen and monitoring plan for a solid organ transplant recipient with an invasive fungal infection.

1. Assess the impact of nonadherence and current challenges for effective adherence assessment in solid organ transplant (SOT) recipients.

2. Distinguish the differences between available adherence monitoring strategies and tools for use in SOT recipients.

3. Evaluate and implement the most appropriate adherence monitoring strategy according to transplant program needs.

4. Develop a management plan to address nonadherence.

1. Evaluate the incidence, risk factors, and complications for weight gain in solid organ transplant recipients.

2. Analyze the pros and cons of surgical weight-loss techniques.

3. Design a medication regimen to increase weight loss before and after transplantation.

4. Develop nonpharmacologic recommendations to increase weight loss before and after transplantation.

5. Assess perioperative factors and techniques that improve posttransplant outcomes.

1. Assess risk factors for postoperative delirium and devise patient-specific treatment strategies.

2. Develop an effective treatment strategy for managing seizures in solid organ transplant (SOT) recipients.

3. Demonstrate an understanding of the pathophysiology and therapeutic approach to posterior reversible encephalopathy syndrome (PRES).

4. Analyze clinical data to create a comprehensive treatment strategy in SOT recipients with progressive multifocal leukoencephalopathy (PML).